Valuation Gilead Sciences, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-12 EDT			5-day change	1st Jan Change
125.59 ^USD	-0.22%		-2.76%	+2.32%

06-09	Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program	MT
06-09	Gilead Sciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:20 PM

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	107,677	100,942	115,118	152,281	155,929	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	2.4%	-	-
Enterprise Value (EV) ¹	118,530	126,522	118,665	131,838	169,585	165,497	155,832	145,522
Change	-	6.74%	-6.21%	11.1%	28.63%	-2.41%	-5.84%	-6.62%
P/E Ratio	14.7x	23.6x	18x	243x	18.1x	-45x	16.3x	14.9x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	8.53x	6.6x	5.25x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.63x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.12x	4.81x	4.56x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	5.43x	4.8x	4.25x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	30x	8.57x	7.61x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	60.1x	10x	8.72x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	163x	11.8x	10.5x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	0.61%	8.5%	9.56%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.246	3.316	2.959
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.58%	2.64%	2.36%
EPS ²	4.93	3.64	4.5	0.38	6.78	-2.791	7.7	8.404
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-116%	43.1%	35.2%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,478	32,450	34,218
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	5,525	18,175	19,128
EBIT ¹	12,548	12,180	10,484	8,520	13,193	2,752	15,569	16,680
Net income ¹	6,225	4,592	5,665	480	8,510	-3,373	9,603	10,404
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	9,568	-96.43	-10,407
Reference price ²	72.61	85.85	81.01	92.37	122.74	125.59	125.59	125.59
Nbr of stocks (in thousands)	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,241,570	-	-
Announcement Date	2/1/22	2/2/23	2/6/24	2/11/25	2/10/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
GILEAD SCIENCES, INC.	-45x	5.43x	29.95x	2.58%	156B
ELI LILLY AND COMPANY	33.15x	12.05x	24.81x	0.6%	1,010B
JOHNSON & JOHNSON	25.74x	5.93x	16.13x	2.22%	580B
ABBVIE INC.	27.88x	6.79x	13.86x	3.01%	402B
ROCHE HOLDING AG	17.71x	4.37x	10.73x	3.04%	330B
MERCK & CO., INC.	53.11x	4.94x	20.09x	2.81%	294B
ASTRAZENECA PLC	22.78x	4.74x	13.47x	1.85%	280B
NOVARTIS AG	21.24x	5.49x	13.32x	2.92%	281B
NOVO NORDISK A/S	12.7x	4.76x	9.73x	3.95%	197B
AMGEN INC.	23.09x	6.16x	10.76x	2.84%	192B
Average	19.24x	6.07x	16.29x	2.58%	372.3B
Weighted average by Cap.	25.08x	7.27x	17.63x	2.15%